MSF Accuses Gilead Of Restricting Hepatitis C Drug Access In Developing Countries

Reuters: Charity attacks Gilead over hepatitis C drug restrictions
“Charity Médecins Sans Frontières has accused U.S. drugmaker Gilead Sciences Inc. of restricting access to its breakthrough hepatitis C drug Sovaldi in developing countries as it tries to protect profit margin in wealthier nations. MSF, also known as Doctors Without Borders, said Gilead’s restrictions aimed to stop discounted supplies of Sovaldi being diverted to patients from rich countries, but that the effort had resulted in ‘multiple restrictions and demands’ on people receiving treatment in poor countries…” (Siddiqui/Berkrot, 3/18).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.